Celgene International Sàrl, a wholly-owned subsidiary of Celgene
Corporation (NASDAQ:CELG), today announced that the latest research
findings on OTEZLA® (apremilast), the Company’s oral, selective
inhibitor of phosphodiesterase 4 (PDE4), in plaque psoriasis and
psoriatic arthritis will be presented at the 23 rd European
Academy of Dermatology and Venereology (EADV) Congress in Amsterdam,
October 8 – 12, 2014.
for Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA® (apremilast) in Plaque Psoriasis and Psoriatic Arthritis at European Academy of Dermatology and Venereology Congress investment picks